Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 304

1.

Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol.

Rabban JT, Krasik E, Chen LM, Powell CB, Crawford B, Zaloudek CJ.

Am J Surg Pathol. 2009 Dec;33(12):1878-85. doi: 10.1097/PAS.0b013e3181bc6059.

PMID:
19898224
2.

Transitional cell metaplasia of fallopian tube fimbriae: a potential mimic of early tubal carcinoma in risk reduction salpingo-oophorectomies from women With BRCA mutations.

Rabban JT, Crawford B, Chen LM, Powell CB, Zaloudek CJ.

Am J Surg Pathol. 2009 Jan;33(1):111-9. doi: 10.1097/PAS.0b013e31817d74a7.

PMID:
18830124
3.

Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.

Rabban JT, Barnes M, Chen LM, Powell CB, Crawford B, Zaloudek CJ.

Am J Surg Pathol. 2009 Aug;33(8):1125-36. doi: 10.1097/PAS.0b013e31819e986a.

PMID:
19440148
4.
5.

Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol.

Powell CB, Chen LM, McLennan J, Crawford B, Zaloudek C, Rabban JT, Moore DH, Ziegler J.

Int J Gynecol Cancer. 2011 Jul;21(5):846-51. doi: 10.1097/IGC.0b013e31821bc7e3.

PMID:
21670699
6.

Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens.

Reitsma W, de Bock GH, Oosterwijk JC, Bart J, Hollema H, Mourits MJ.

Eur J Cancer. 2013 Jan;49(1):132-41. doi: 10.1016/j.ejca.2012.07.021. Epub 2012 Aug 21.

PMID:
22921157
7.
8.

Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.

Powell CB, Kenley E, Chen LM, Crawford B, McLennan J, Zaloudek C, Komaromy M, Beattie M, Ziegler J.

J Clin Oncol. 2005 Jan 1;23(1):127-32.

9.

Correlation of macroscopic and microscopic pathology in risk reducing salpingo-oophorectomy: implications for intraoperative specimen evaluation.

Rabban JT, Mackey A, Powell CB, Crawford B, Zaloudek CJ, Chen LM.

Gynecol Oncol. 2011 Jun 1;121(3):466-71. doi: 10.1016/j.ygyno.2011.01.031. Epub 2011 Feb 24.

PMID:
21353295
10.

Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.

Manchanda R, Abdelraheim A, Johnson M, Rosenthal AN, Benjamin E, Brunell C, Burnell M, Side L, Gessler S, Saridogan E, Oram D, Jacobs I, Menon U.

BJOG. 2011 Jun;118(7):814-24. doi: 10.1111/j.1471-0528.2011.02920.x. Epub 2011 Mar 10.

11.

Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.

Lamb JD, Garcia RL, Goff BA, Paley PJ, Swisher EM.

Am J Obstet Gynecol. 2006 Jun;194(6):1702-9.

PMID:
16731090
12.

Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.

Rebbeck TR, Kauff ND, Domchek SM.

J Natl Cancer Inst. 2009 Jan 21;101(2):80-7. doi: 10.1093/jnci/djn442. Epub 2009 Jan 13.

13.

The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome.

Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, Garber JE, Cramer DW, Crum CP.

Am J Surg Pathol. 2006 Feb;30(2):230-6.

PMID:
16434898
15.

Diathermy-induced injury may affect detection of occult tubal lesions at risk-reducing salpingo-oophorectomy.

Manchanda R, Silvanto A, Abdelraheim A, Burnell M, Johnson M, Saridogan E, Rosenthal AN, Brunell C, Aslam N, Vashisht A, Pandis G, Jacobs I, Menon U, Benjamin E.

Int J Gynecol Cancer. 2012 Jun;22(5):881-8. doi: 10.1097/IGC.0b013e31824b4093.

PMID:
22572844
16.

Does risk-reducing bilateral salpingo-oophorectomy leave behind residual tube?

Cass I, Walts A, Karlan BY.

Gynecol Oncol. 2010 Apr;117(1):27-31. doi: 10.1016/j.ygyno.2009.12.023. Epub 2010 Jan 27.

PMID:
20110118
17.

Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.

Kauff ND, Barakat RR.

J Clin Oncol. 2007 Jul 10;25(20):2921-7. Review.

PMID:
17617523
18.

Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers.

Domchek SM, Friebel TM, Garber JE, Isaacs C, Matloff E, Eeles R, Evans DG, Rubinstein W, Singer CF, Rubin S, Lynch HT, Daly MB, Weitzel J, Ganz PA, Pichert G, Olopade OI, Tomlinson G, Tung N, Blum JL, Couch F, Rebbeck TR.

Breast Cancer Res Treat. 2010 Nov;124(1):195-203. doi: 10.1007/s10549-010-0799-x. Epub 2010 Feb 24.

19.

Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status.

Colgan TJ, Murphy J, Cole DE, Narod S, Rosen B.

Am J Surg Pathol. 2001 Oct;25(10):1283-9.

PMID:
11688463
20.

Pathologic findings in prophylactic oophorectomy specimens in high-risk women.

Leeper K, Garcia R, Swisher E, Goff B, Greer B, Paley P.

Gynecol Oncol. 2002 Oct;87(1):52-6.

PMID:
12468342
Items per page

Supplemental Content

Write to the Help Desk